Skip to main content
SELLAS Life Sciences Group, Inc. logo

SELLAS Life Sciences Group, Inc. — Investor Relations & Filings

Ticker · SLS ISIN · US81642T2096 LEI · 549300VZIH50VYURLQ98 US Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2011-04-14 Board/Management Inform…
Country US United States of America
Listing US SLS

About SELLAS Life Sciences Group, Inc.

https://www.sellaslifesciences.com/

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's core activity involves advancing its pipeline of cancer immunotherapies, which are designed to utilize the patient's immune system to combat various malignancies. Its development programs aim to address significant unmet medical needs in oncology by creating new treatment options for cancer patients.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 13, 2011, reporting multiple corporate events: completion of an acquisition (merger) of Apthera, Inc., entry into material definitive agreements related to the merger (Contingent Value Rights Agreement and Escrow Agreement), and appointments of new executive officers (Executive Vice President and COO, and Vice President and CFO). The document includes detailed descriptions of these events, including terms of employment agreements and stock option grants. The primary focus is on the announcement of the acquisition completion and management changes. There is no financial statement or detailed financial analysis included, nor is it a full annual or quarterly report. The document is not a proxy statement, earnings release, or other report type. Given the detailed disclosure of management appointments and departures, the appropriate classification is Board/Management Information (MANG).
2011-04-14 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes detailed disclosures about a merger agreement, management changes including the resignation of the CEO and appointment of a new CEO, and related compensatory arrangements. These topics align with announcements of material definitive agreements and changes in senior management. The presence of detailed descriptions of the merger terms and management appointments indicates this is not a simple announcement but a regulatory filing reporting significant corporate events. Form 8-K filings typically fall under Regulatory Filings (RNS) in classification schemes unless they are specifically about management changes or mergers. However, since this document covers both a merger agreement and management changes, and is a current report (8-K), the best fit is Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not neatly fit into other categories like MANG or TAR, which are usually more narrowly focused. The document is lengthy (15,000 characters) and contains substantive information, not just a brief announcement or certification, so it is not RPA or a certification. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2011-04-05 English
RXI PHARMACEUTICALS CORPORATION
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It specifically states that the company, RXi Pharmaceuticals Corporation, is delaying the filing of its Form 10-K for the period ending December 31, 2010, and explains the reason for the delay. The document does not contain the actual 10-K report or any financial data, but rather is a notification about the late filing of the 10-K. The document length is 3511 characters, which is relatively short and consistent with a notification rather than a full report. According to the rules, such a notification is classified as a Regulatory Filing (RNS) because it is a compliance document related to filing deadlines and does not contain substantive financial information or the report itself.
2011-03-31 English
FORM 4 SUBMISSION
Director's Dealing
2011-03-29 English
FORM 4 SUBMISSION
Director's Dealing
2011-03-29 English
FORM 4 SUBMISSION
Director's Dealing
2011-03-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.